arrow
H

Hiroki Osumi

Kanagawa Cancer Center
H指数:20
被引数:1,585

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: An integrated analysis of four phase III randomized controlled trials (JCOG2310A-S4)

II/III期结直肠癌根治性切除术后时间依赖性复发模式:四项III期随机对照试验的整合分析(JCOG2310A-S4)

2026-07-230
PRE
Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience

Zolbetuximab联合化疗在Claudin 18亚型2阳性晚期胃癌中的安全性与有效性:真实世界经验的初步报告

2025-12-180
OAAI
Glucocorticoids rarely required in granulocyte colony-stimulating factor-associated large-vessel vasculitis: Japanese cancer centre cohort

糖皮质激素在粒细胞集落刺激因子相关大血管血管炎中很少需要:日本癌症中心队列

2025-12-010
PRE
Early Higher Plasma Regorafenib Concentration Predicts Shorter PFS in Japanese Patients With mCRC

早期较高的血浆瑞戈菲布浓度预示日本结直肠癌患者无进展生存期缩短

2025-11-040
OAAI
Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High)

循环肿瘤DNA在HER2阳性晚期胃癌中的临床意义:一项关于HER2和PD-1双靶向疗法(Ni-High)的 Ib 期临床试验的协作研究

2025-09-120
OA
Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

使用术前血管内皮生长因子抑制剂的既往用药对三氟尿idine/替吡拉塞联合贝伐珠单抗在转移性结直肠癌患者中安全性与有效性的影响

2025-07-210
PRE
Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings

早期肿瘤缩小对接受曲妥珠单抗德鲁替康治疗的三线或更后线治疗的HER2阳性晚期胃癌患者生存结局的影响

2025-04-240
OA
Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma

多西他赛、顺铂和5-氟尿嘧啶新辅助治疗局部晚期食管鳞状细胞癌的真实世界安全性和有效性

2025-04-080
OAAI
Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023

调查2011年至2023年间免疫疗法在HER2阴性晚期胃癌真实世界患者中的作用

2025-02-240
OA